DexComDXCM

NASDAQ · USA · Segment 1 of 8 in the Medicine, pharma & life science value chain: Diabetes & metabolic disease

American medtech company focused on continuous glucose monitoring (CGM) for people with diabetes.

Diabetes & metabolic disease: Treatment and monitoring of diabetes and metabolic disease — from insulin to glucose monitoring.

Key metrics

Market cap

$28.1B

Price

$75.00

Today

+2.7%

Return YTD

+10.0%

Return 1Y

−14.0%

P/E

30.2

P/S

5.8

P/B

9.5

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

DiabetesGlucose monitoringMedtech exposureDigital health

In the value chain

Products & services

CGM sensors (G-series)
Stelo (OTC)
Diabetes software

Competitors

Abbott (Libre)
Medtronic
Insulet

Risks

Price competition
Reimbursement changes

Same segment: Diabetes & metabolic disease

Eli LillyLLY InsuletPODD

See where DexCom sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →